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Introduction 
Leishmaniases are a collection of human diseases caused by protozoan parasite species that 
belong to the genus Leishmania.  Parasites are transmitted by the bite of infected female 
sandflies.  Humans are secondary targets of infection, with rodents, sloths, and dogs being the 
primary reservoirs of parasites that are infectious to man (Liew et al. 1993).  Currently there is 
no vaccine available, and leishmaniases are endemic in 88 countries, with 350 million people at 
risk.  An estimated 12 million people are infected worldwide, with 1.5 – 2 million new cases 
each year. The three main clinical manifestations are cutaneous, mucocutaneous, and visceral 
disease.  Cutaneous disease manifests as skin ulcerations that typically heal spontaneously.  
Mucocutaneous disease afflicts (peri)-oral and (peri)-nasal mucosal tissue, resulting in severe 
disfiguration due to extensive tissue destruction. This study focuses on visceral leishmaniasis 
(VL), which is caused by Leishmania donovani, L. chagasi, and L. infantum.  There are 
approximately 500,000 new cases of VL annually, with over 90% of the cases occurring in 
Bangladesh, Nepal, India, Brazil, and Sudan (WHO Factsheet).  VL causes profound 
hepatosplenomegaly due to widespread dissemination of parasites throughout the 
reticuloendothelial system.  Other symptoms include fever, malaise, weight loss, and anemia 
(Liew et al. 1993, Roberts et al. 2000).  Visceral disease is fatal without chemotherapeutic 
intervention, and is sometimes fatal even with treatment (Roberts et al. 1993).   Current drug  
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treatment options include antimonials, amphotericin B, and miltefosine.  However, none of these 
drugs is an ideal treatment option due to high costs, adverse side effects, and emerging drug 
resistance (Murray et al. 2005). 
Leishmania species are particularly challenging to treat, because they parasitize host 
macrophages – phagocytic cells that are normally responsible for the uptake and clearance of 
invading microorganisms. Parasites actively replicate in parasitopherous vacuoles within the 
macrophage, and evade immune detection by dampening normal macrophage antimicrobial 
responses. Parasites are able to alter the antigen presenting functions and MHC class II 
expression of macrophages, both of which are necessary for effective T-cell communication and 
activation. Macrophage-T-cell interactions are key because the activation of certain T-cell 
subsets leads to the production of inflammatory cytokines that can activate macrophages to 
effectively kill parasites (Alexander and Russell 1992).  Early immunological studies in mice 
infected with L. major, a parasite that causes self-limiting cutaneous disease, revealed that type 1 
T helper cell (Th1) responses involving the production of cytokines such as IFN-γ, IL-12 and 
TNF-α by immune cells results in the killing of parasites within macrophages and resolution of 
infection, whereas type 2 T helper cell (Th2) responses involving the production of IL-4, IL-13 
and IL-10 by immune cells is associated with disease exacerbation and non-healing phenotypes 
(Alexander and Bryson 2005). However, the role of Th1/Th2 type responses is not as 
straightforward in VL, as IL-4 has been shown to be necessary for the success of certain drug 
treatments (Alexander et al. 2000), even though inhibition of IL-10 is protective (Murray et al. 
2002).  Nonetheless, the development of a strong Th1 response with the production of IFN-γ and 
IL-12 is critical for parasite clearance (Taylor and Murray 1997, Murray and Delph-Etienne 
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2000, Murray et al. 2006).  In fact, granuloma formation in the liver, which is required for 
resolution of disease, is IFN-γ dependent (Murray and Delph-Etienne 2000). 
Materials and Methods 
Mice.  Eight to twelve week old BALB/c wild-type (WT) mice purchased from Harlan 
laboratories (Indianapolis, IN) were used for all experiments. 
Parasite.  Sudan strain L. donovani was harvested from the spleens of sick Golden Syrian 
hamsters.  Mice were infected with 10 million amastigotes in a volume of 100 ml intravenously 
(i.v.) via tail vein injection. 
Clodronate. Liposomal clodronate was obtained from Dr. Van Rooijen 
(www.clodronateliposomes.org).  Mice were initially injected with 200 ml i.v. via the tail vein 
and 400 ml intraperitoneally (i.p.).  For timepoints beyond 7 days post drug treatment mice were 
re-treated 7 days after the initial treatment with 100 ml i.v. and 200 ml i.p.   Controls received 
PBS containing liposomes. 
Parasite Burdens.  Impression smears of spleens and livers harvested from drug-treated and 
control mice were made on glass slides.  These slides were then stained with Giemsa.  Parasites 
and nucleated host cells were counted.  Leishman-Donovan units (LDUs) were then calculated as 
the number of parasites per 1000 nucleated cells to express parasite levels. 
ELISA.  Splenocytes harvested from drug-treated and control mice were plated at a 
concentration of 0.5 million cells per well in triplicate in 96 well plates.  Cells were then 
stimulated with 20 mg/ml of soluble L. donovani antigen obtained from repeated freeze thaw 
cycles.  Cell supernatants were collected 72 hours after stimulation and levels of secreted IFN-γ, 
IL-12, IL-4, and IL-10 were then measured using an enzyme-linked immunosorbent assay 
(ELISA). 
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Histopathology.  Tissue sections from the livers and spleens of drug-treated and control mice 
were collected and sent for histological processing at The Ohio State University Core Pathology 
Facility.  Tissues were cut into 6 micron sections and stained with hematoxylin and eosin. 
The analysis performed at each timepoint is shown in Figure 1. 
Results and Discussion 
Preliminary Data. Recently, our laboratory found that STAT-1 and T-bet, transcription factors 
which both play a key role in IFN-γ signaling and production by CD4+ Th1 cells (fig. 2), 
unexpectedly play distinct roles in the outcome of VL.  Both T-bet and STAT-1 knock-out (KO) 
mice on a BABL/c background were unable to mount Th1 responses, as evidenced by cytokine 
ELISA data. However, liver and spleen parasite burdens showed that STAT-1 KO mice were 
unexpectedly resistant to infection, while T-bet mice were highly susceptible.  Further analysis 
revealed that STAT-1 KO mice have severe impairments in both T-cell (data not shown) and 
macrophage trafficking (fig. 3) to the liver following infection (Rosas et al. 2006).  Since Rag2 
KO mice, which lack T-cells, are highly susceptible to L. donovani infection, we hypothesize 
that the resistant phenotype seen in STAT-1 KO mice is due to the reduction in macrophage, and 
not T-cell, trafficking to the liver. Clodronate containing liposomes have been shown to deplete 
macrophages via apoptosis, particularly splenic macrophages and Kupffer cells – resident liver 
macrphages (Van Rooijen 1989).  Clodronate (fig. 4) is a bisphosphonate drug used to inhibit 
osteoclast activity in patients with osteolytic bone diseases (www.clodronateliposomes.org).  To 
determine the role of macrphages in L. donovani infection, wild-type (WT) BALB/c mice were 
treated clodronate-containing liposomes (control mice were treated with PBS containing 
liposomes) both pre- and post-L. donovani infection. 
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Clodronate treated mice had markedly reduced parasite burdens.  Mice treated with 
clodronate liposomes both 2 days prior to infection (fig 5a) or 1 (fig 5b) or 6 days (fig 5c) post-
infection had significantly reduced parasite burdens in both their livers (fig 5) and spleens (data 
not shown) compared to PBS controls. The presented data indicate that macrophage depletion 
both early and late in infection is capable of reducing parasite burdens in the tissues affected by 
L. donovani. These effects most likely result from the elimination of actively infected 
macrophages and the elimination of monocytes that could potentially serve as future reservoirs 
of infection.  Without the presence of host cell macrophages to parasitize, L. donovani die off 
within their hosts.  It is important to note, however, that the macrophage depletion afforded by 
clodronate treatment is transient, and repopulation of blood moncytes in mice begins within eight 
days.   
Clodronate treatment appears to dampen immune responses.  Stimulated immune cells 
isolated from the spleens of mice treated with clodronate 2 days prior to infection had reduced 
levels of IFN-γ, IL-12, IL-4, and IL-10 as measured by ELISA (fig 6a).  A similar trend was seen 
in mice treated with clodronate 1 day (data not shown – trend is the same as seen in fig 6b) and 6 
days (fig 6b) post-infection, with the exception of elevated IL-4. This data indicates that 
macrophage depletion dampens the overall immune response following infection, with the 
exception of IL-4 production in mice treated post-infection.  This reduction of IFN-γ is not 
surprising, because the production of IFN-γ by T cells is dependent on their activation via 
macrophage communication.  Additionally, IL-12 and IL-10 are cytokines mainly secreted by 
macrophages, so following depletion one would expect to see reduced levels.  IL-4 is a cytokine 
produced exclusively by Th2 CD4+ T-cells.  It is probably reduced in mice treated with 
clodronate prior to infection because no macrophages are ever infected, and therefore no immune 
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response is ever initiated.  It is probably seen elevated in mice treated post-infection, however, 
because the initial macrophage infection is capable of stimulating T-cell differentiation.  
However, without a sustained macrophage signal (the signal is lost due to cloronate depletion) 
the default program of differentiating T-cells is into the Th2 subset, which secretes IL-4. 
Early clodronate treatment reduces liver immunopathology.  Mice treated with clodronate 2 
days prior (data not shown – similar to fig 7a) to infection or 1 day post infection (fig 7a) showed 
little or no immunopathology when compared to PBS treated controls which exhibited diffuse 
foci of inflammation and granuloma formation.  However, mice treated with clodronate 6 days 
post-infection showed immunopathology similar to PBS controls (fig 7b), despite their low 
parasite load (fig 5c). These data indicate that while BALB/c WT mice have established 
infection and developed immunopathology by day 6 in their livers, clodronate treament is still 
effective in eliminating parasites following the induction of macrophage apoptosis. 
Implications 
 This research may aid in the initial development of new drug treatment options for 
visceral leishmaniasis.  Many of the current treatment options are very expensive and require 
long hospital stays because they must be administered intravenously over time.  While 
miltefosine is administered orally, patient noncompliance could lead to the development of 
resistance against this drug.  Clodronate, or other drugs that induce macrophage apoptosis, could 
ideally be administered as 1-2 injections in a clinical setting, eliminating the need for hospital 
stays.  Also, due to clodronate’s mechanism of action, patient noncompliance and drug resistance 
would not be an issue.  Additionally, other diseases in which pathogens reside and multiply 
within host cell macrophages, such as tuberculosis, could benefit from the development of a drug 
that selectively and temporarily depletes host cell macrophages. 
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Figure 2. Diagram of IFN− γ signaling in CD4+ T cells 
Figure 1. General scheme of timepoint analysis. 
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Figure 4. Clodronate Structure 
 
Figure 3. Flow cytometry 
data of L. donovani infected 
mouse liver tissue.  
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ICAM-1b and CD11b. 
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Figure 5.  Parasite burdens in the liver  of mice 
treated with clodronate 2 days prior to infection 
(a), 1 day (b), or 6 days post-infection.  Data 
are represented as LDUs.  Each bar 
represents the mean of data obtained from 3-4 
mice.  Error bars represent standard error. 
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Figure 6.  Cytokine production from the supernatants of stimulated splenocytes harvested from mice treated 2 
days prior to infection (a) or 6 days post infection (b) with clodronate, measured using ELISA.  Data represent 
the means generated from triplicate samples of 3-4 mice per group.  Error bars indicate standard error. 
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Figure 7.  Histopathology from mice treated with clodronate 1 day (a) or 6 days (b) after infection.  
Arrowheads indicate granulomas.  
